poractant alfa (Curosurf)

09/01/1998 - "Efficacy of Curosurf in a rat model of acute respiratory distress syndrome."
04/22/2000 - "Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial."
05/01/2020 - "Pharmacoeconomic evaluation of different doses of Curosurf for treating neonatal acute respiratory distress syndrome."
03/01/2020 - "Although current evidence suggests that initial dose of 200 mg/kg poractant alfa reduces mortality in the treatment of respiratory distress syndrome (RDS), these data were obtained in a highly heterogeneous group of patients and neither of them addressed mortality as primary outcome. "
01/01/2017 - "In Vivo Evaluation of the Acute Pulmonary Response to Poractant Alfa and Bovactant Treatments in Lung-Lavaged Adult Rabbits and in Preterm Lambs with Respiratory Distress Syndrome."

09/01/1998 - "In conclusion, Curosurf treatment improved respiratory frequency and decreased mortality, pulmonary oedema and inflammation. "
01/01/2009 - "Previously, Curosurf was demonstrated to increase inflammation in allergic asthmatics. "
01/01/2006 - "We conclude that HA added to 50 mg/kg Curosurf or use of 100 mg/kg Curosurf with or without HA provides the best effects in terms of lung function and reduction of inflammation."
01/01/2003 - "In very premature infants treated with poractant alfa for established RDS, early barotrauma and postnatal local and/or systemic inflammation are strongly associated with the subsequent development of severe BPD."
01/01/2021 - "This study indicates that single dose of CHF5633 improves lung function and attenuates inflammation as effectively as poractant alfa in experimental ARDS caused by injurious ventilation."

01/01/2022 - "Non-invasive administration of poractant-α in neonatal respiratory distress syndrome via a supraglottic device in the clinical practice in a second level neonatal unit: comparison of LMA® vs iGel® devices."
01/01/1990 - "European multicenter trials of curosurf for treatment of neonatal respiratory distress syndrome."
09/01/1994 - "A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome."
01/01/2020 - "Aim: To evaluate the effect of the initial dose of poractant alfa on clinical outcomes in neonatal respiratory distress syndrome (RDS) and to assess adherence to treatment guidelines recommending a dose of 200 mg/kg. Methods: Records of neonates who received poractant alfa with a less invasive technique (LISA) or with the INtubate-SURfactant-Extubate (INSURE) technique were retrieved from the aggregated datasets of three prospective RDS studies conducted between 2015 and 2019. "
06/01/2005 - "A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome."

05/01/2005 - "As a whole, Curosurf is an effective component of combined intensive therapy for acute respiratory failure in pediatric cardiosurgery."
10/23/2006 - "The purpose of this study was to examine the efficiency of a single dose of fast-acting exogenous surfactant (Curosurf) given to premature babies with progressive respiratory insufficiency. "
08/01/1998 - "The aim of this study was to compare the effects of modified porcine surfactant (Curosurf) given either by a simplified slow delivery technique or by the standard bolus method, on pulmonary gas exchange, lung mechanics, and surfactant distribution in rats with respiratory failure produced by lung lavage. "
01/01/2020 - "Nebulized Poractant Alfa Reduces the Risk of Respiratory Failure at 72 Hours in Spontaneously Breathing Surfactant-Deficient Newborn Piglets."
05/01/2005 - "[Use of the exogenous surfactant curosurf in combined therapy for acute respiratory failure in children after cardiosurgical interventions]."

01/01/2020 - "Nebulized poractant alfa was more effective at doses higher than 100 mg/kg and was associated with similar pulmonary, hemodynamic, and cerebral behavior to that in the Insure group, but improved lung injury scores. "
12/01/2017 - "Prophylactic Curosurf administration did not improve lung injury scores or compliance in triple KO mice."
01/01/2023 - "CHF5633 improved survival and alleviated meconium-induced lung injury, the same as Poractant alfa. "
01/01/2023 - "Similar effects on improving survival and alleviating lung injury were found between CHF5633 and Poractant alfa. "
01/01/2023 - "CHF5633 had similar benefits in improving survival and alleviating lung injury as Poractant alfa. "